These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21126217)

  • 1. Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model.
    Favaro P; Finn JD; Siner JI; Wright JF; High KA; Arruda VR
    Hum Gene Ther; 2011 Jul; 22(7):843-52. PubMed ID: 21126217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype.
    Grimm D; Pandey K; Nakai H; Storm TA; Kay MA
    J Virol; 2006 Jan; 80(1):426-39. PubMed ID: 16352567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing transduction of the liver by adeno-associated viral vectors.
    Nathwani AC; Cochrane M; McIntosh J; Ng CY; Zhou J; Gray JT; Davidoff AM
    Gene Ther; 2009 Jan; 16(1):60-9. PubMed ID: 18701909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.
    Sen D; Gadkari RA; Sudha G; Gabriel N; Kumar YS; Selot R; Samuel R; Rajalingam S; Ramya V; Nair SC; Srinivasan N; Srivastava A; Jayandharan GR
    Hum Gene Ther Methods; 2013 Apr; 24(2):104-16. PubMed ID: 23442071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.
    Nathwani AC; Rosales C; McIntosh J; Rastegarlari G; Nathwani D; Raj D; Nawathe S; Waddington SN; Bronson R; Jackson S; Donahue RE; High KA; Mingozzi F; Ng CY; Zhou J; Spence Y; McCarville MB; Valentine M; Allay J; Coleman J; Sleep S; Gray JT; Nienhuis AW; Davidoff AM
    Mol Ther; 2011 May; 19(5):876-85. PubMed ID: 21245849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Host and vector-dependent effects on the risk of germline transmission of AAV vectors.
    Favaro P; Downey HD; Zhou JS; Wright JF; Hauck B; Mingozzi F; High KA; Arruda VR
    Mol Ther; 2009 Jun; 17(6):1022-30. PubMed ID: 19293773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males.
    Arruda VR; Fields PA; Milner R; Wainwright L; De Miguel MP; Donovan PJ; Herzog RW; Nichols TC; Biegel JA; Razavi M; Dake M; Huff D; Flake AW; Couto L; Kay MA; High KA
    Mol Ther; 2001 Dec; 4(6):586-92. PubMed ID: 11735343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant adeno-associated virus-mediated in utero gene transfer gives therapeutic transgene expression in the sheep.
    David AL; McIntosh J; Peebles DM; Cook T; Waddington S; Weisz B; Wigley V; Abi-Nader K; Boyd M; Davidoff AM; Nathwani AC
    Hum Gene Ther; 2011 Apr; 22(4):419-26. PubMed ID: 20919876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model.
    Mattar CNZ; Gil-Farina I; Rosales C; Johana N; Tan YYW; McIntosh J; Kaeppel C; Waddington SN; Biswas A; Choolani M; Schmidt M; Nathwani AC; Chan JKY
    Mol Ther; 2017 Aug; 25(8):1843-1853. PubMed ID: 28462816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theodore E. Woodward Award. AAV-mediated gene transfer for hemophilia.
    High KA
    Trans Am Clin Climatol Assoc; 2003; 114():337-51; discussion 351-2. PubMed ID: 12813929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.
    Shao W; Earley LF; Chai Z; Chen X; Sun J; He T; Deng M; Hirsch ML; Ting J; Samulski RJ; Li C
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.
    Grimm D; Zhou S; Nakai H; Thomas CE; Storm TA; Fuess S; Matsushita T; Allen J; Surosky R; Lochrie M; Meuse L; McClelland A; Colosi P; Kay MA
    Blood; 2003 Oct; 102(7):2412-9. PubMed ID: 12791653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adeno-associated virus (AAV) capsid genes isolated from rat and mouse liver genomic DNA define two new AAV species distantly related to AAV-5.
    Lochrie MA; Tatsuno GP; Arbetman AE; Jones K; Pater C; Smith PH; McDonnell JW; Zhou SZ; Kachi S; Kachi M; Campochiaro PA; Pierce GF; Colosi P
    Virology; 2006 Sep; 353(1):68-82. PubMed ID: 16806384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence.
    Wang Z; Lisowski L; Finegold MJ; Nakai H; Kay MA; Grompe M
    Mol Ther; 2012 Oct; 20(10):1902-11. PubMed ID: 22990673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.
    Markusic DM; Nichols TC; Merricks EP; Palaschak B; Zolotukhin I; Marsic D; Zolotukhin S; Srivastava A; Herzog RW
    J Transl Med; 2017 May; 15(1):94. PubMed ID: 28460646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.
    Ge Y; Powell S; Van Roey M; McArthur JG
    Blood; 2001 Jun; 97(12):3733-7. PubMed ID: 11389010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vector Affinity and Receptor Distribution Define Tissue-Specific Targeting in an Engineered AAV Capsid.
    Martino RA; Wang Q; Xu H; Hu G; Bell P; Arroyo EJ; Sims JJ; Wilson JM
    J Virol; 2023 Jun; 97(6):e0017423. PubMed ID: 37199615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates.
    Salas D; Kwikkers KL; Zabaleta N; Bazo A; Petry H; van Deventer SJ; Aseguinolaza GG; Ferreira V
    Blood Adv; 2019 Sep; 3(17):2632-2641. PubMed ID: 31501158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.